Stéphane Éderhy
Inserm · 491 works · 18,854 citations · h-index 49
Top works
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
- 2023 ESC Guidelines for the management of endocarditis
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity
- Myocarditis in the Setting of Cancer Therapeutics
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
- Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis
- Management of hypertension in angiogenesis inhibitor-treated patients
- Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis
- Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis
- HIV and Coronary Heart Disease
- Cardiac troponin‐I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center
- Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
- Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
- Abstract Supplement ACR Convergence 2021
- Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors
- Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial
- Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
- Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis